RT Journal Article
T1 Patients with Schizophrenia Showed Worse Cognitive Performance than Bipolar and Major Depressive Disorder in a Sample with Comorbid Substance Use Disorders
A1 Marquez-Arrico, Julia E.
A1 González-Sánchez, Álvaro
A1 Navarro-Humanes, José Francisco
A1 Penadés, Rafael
A1 Adan-Puig, Ana
K1 Esquizofrenia
AB Comorbidity of substance use disorders (SUD) and severe mental illness (SMI) is highly frequent in patients, the most common diagnoses being schizophrenia (SZ), bipolar disorder (BD) and major depressive disorder (MDD). Since comorbidity has its own clinical features, and neurocognitive functioning is not always similar to psychiatric symptoms the present study explores the cognitive performance of patients with dual disorders. A neuropsychological battery of tests was used to assess 120 under treatment male patients, 40 for each group considered (SZ + SUD, BD + SUD and MDD + SUD) who were mainly polyconsumers. Significant differences (with premorbid IQ as a covariate) were found among the groups, with SZ + SUD having a worse performance in attention, verbal learning, short term memory and recognition. The consideration of a global Z score for performance evidenced an impaired neurocognitive pattern for SZ + SUD compared with BD + SUD and MDD + SUD. According to norms, all patients showed difficulties in verbal learning, short-term memory and recognition. Our research indicated that the neurocognitive functioning of dual disorder patients was influenced by the comorbid SMI, with SZ + SUD presenting major difficulties. Future studies should thoroughly explore the role of such difficulties as indicators or endophenotypes for dual schizophrenia disorders, and their usefulness for prevention and treatment.
PB IOAP-MPDI
YR 2022
FD 2022-11-09
LK https://hdl.handle.net/10630/25887
UL https://hdl.handle.net/10630/25887
LA eng
NO Marquez-Arrico JE, Gonzalez-Sanchez A, Navarro JF, Penadés R, Adan A. Patients with Schizophrenia Showed Worse Cognitive Performance than Bipolar and Major Depressive Disorder in a Sample with Comorbid Substance Use Disorders. Journal of Clinical Medicine. 2022; 11(22):6648. https://doi.org/10.3390/jcm11226648
NO This research was funded by the grant PID2020-117767GB-I00 of Spanish Ministry of Science and Innovation (MCIN/AEI/10.13039/501100011033) and the Generalitat de Catalunya (2017SGR-748). Partial funding for open access charge: Universidad de Málaga
DS RIUMA. Repositorio Institucional de la Universidad de Málaga
RD 21 ene 2026